Tim Anderson
Tim Anderson
Timothy Devon Andersonis an American professional baseball shortstop for the Chicago White Sox of Major League Baseball. Anderson played college baseball at East Central Community College, and was selected in the first round of the 2013 MLB draft by the White Sox. He made his MLB debut on June 10, 2016...
ProfessionBaseball Player
Date of Birth23 June 1993
ahead company consensus expect good guidance negative
We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.
good negative people quarter time wary
The quarter was good in that they didn't have anything negative at a time when a lot of people are wary about earnings,
good growth pivotal
The real pivotal one will be Claritin, ... You could see some very good growth there.
bad good quarter quiet
It was a good quarter and quiet with no surprises, which is never a bad thing.
base business coming good names
There are some names out there, like Wyeth, for example, that, you know, the base business is in good enough shape, where they actually don't need much coming out of the pipeline,
forward good looks moves moving
Anything that moves it forward is a good thing, and this looks like it's moving forward.
areas brings deal good management shows
This is a pretty good deal for King. It brings them into new therapeutic areas and shows management is aggressive.
burnt fortune good great hole knocking last putt
I had the good fortune of knocking my 2-3-foot putt in on the last hole and Doug's just burnt the edge. He was a great competitor.
bad good negative products
You've got the good with the bad with the sector, ... The good being that you've got good products and fundamentals and the bad being that you've got some negative headlines.
bounce statement team
We just had to bounce back strong. This was a statement our team had to make.
believes hope money private sector
The private sector believes they can make money at this, and we hope they do.
difficulty raising reached stock target
The stock has reached our target of $44 and we have difficulty raising it much from here.
coming convert depends few generation next people quarters second shoes visibility
Schering will be coming out with a second generation (Claritin) drug in the next few months, so it depends how many people they convert (to the new drug), ... They could be in Merck's shoes a few quarters from now, but I don't think they have the visibility to say.
earnings growth guidance revenue seems tells
Merck tells an interesting story, yet the five-year revenue and earnings growth guidance seems far-fetched.